ROCKVILLE, Md., Nov. 17, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Peter A. Clausen, Ph.D., Vice President of Technology and Business Development at Cytomedix, will deliver a podium presentation of data underlying the scientific and clinical rationale for the use of the Company's AutoloGel™ System to effect rapid healing of chronic wounds at the Desert Foot Conference 2010: the 7th Annual High Risk Diabetic Foot Conference being held from November 17—19, 2010 at the Fairmont Scottsdale in Scottsdale, Arizona.
On Wednesday, November 17th, from 3:00 – 3:30 p.m. Pacific Time, Dr. Clausen will deliver a presentation entitled, "The Scientific Rationale for Platelet Rich Plasma to Augment Wound Repair" in the Conference's main lecture hall.
The AutoloGel System is a device for the production of autologous platelet rich plasma ("PRP") gel and is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use on a variety of exuding wounds. Its patent-protected formulation provides physiologically relevant concentrations of PRP that are optimal for wound healing.
Commenting on the presentation, Martin P. Rosendale, President and CEO of Cytomedix, Inc., said, "The Desert Foot Conference is an important meeting for Cytomedix as it is one of the best attended educational meetings for our target audience of podiatrists and other healthcare professionals who manage diabetic foot ulcers. All Veterans Administration (VA) and Department of Defense (DoD) podiatrists and healthcare professionals are provided complimentary registration which results in a significantly large audience of our target market in this area. Not surprisingly, this important conference has been oversold for some time."
"We are especially pleased to have Dr. Clausen present the scientific and clinical rationale for the use of AutoloGel to manage these complex and chronic wounds as they continue to be a growing problem with significant unmet medical need," added Mr. Rosendale.
About the Desert Foot Conference 2010
The Desert Foot Conference is an educational program that is designed to enable participants to improve clinical care for patients with diabetes and enhance communication among physicians and other foot care professionals. It serves as a resource to obtain up to date information on theory and management of diabetic foot disorders and as a venue to highlight research into the Diabetic Foot. The Desert Foot Conference 2010 emphasizes the importance of incorporating effective treatment strategies for limb preservation based on available evidence and the need for a multidisciplinary team approach.
The Desert Foot Conference 2010 is headed by Conference Chairman Robert G. Frykberg, DPM, MPH and Scientific Committee Co-Chairs Jeffrey Robbins, DPM, Dane Wukich, MD and Cynthia Fleck, RN, MBA.
About Cytomedix, Inc.
Cytomedix develops, sells and licenses regenerative biological therapies primarily for wound care, inflammation and angiogenesis. The Company markets the AutoloGel™ System, a device for the production of platelet rich plasma (PRP) gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (PPP) and PRP in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from PPP. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its products, as well as opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics while actively seeking complementary products for the wound care market. Cytomedix also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing or sale. Most notably is its anti-inflammatory peptide (designated CT-112) that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated, the Company's ability to successfully integrate the Angel® and activAT® product lines into its existing business, to assume and satisfy certain liabilities related to the Angel® and activAT® product lines, or its ability to service the deferred payments related to the acquisition of the Angel® and activAT® product lines. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.